| Ticker: BTRN | Building 75, Third Avenue, Charlestown Navy Yard | |
| Exchange: NASDAQ-National Market | Charlestown, Massachusetts 02129 | |
| Industry: Manufacturing | (617) 241-5200 |
| Type of Shares: | Common Shares | Filing Date: | 8/15/94 | |
| U.S. Shares: | 2,800,000 | Offer Date: | 5/8/96 | |
| Non-U.S. Shares: | 0 | Filing Price: | $5.00 | |
| Primary Shares: | 2,800,000 | Offer Price: | $9.50 | |
| Secondary Shares: | 0 | Gross Spread: | $0.67 | |
| Offering Amount: | $14,000,000 | Selling: | $0.40 | |
| Expenses: | $450,000 | Reallowance: | $0.10 | |
| Shares Out After: | 8,128,748 |
| Manager | Tier | Phone |
| UBS Securities Inc. | Lead Manager | (212) 230-4000 |
| Pacific Growth Equities | Co-manager | (415) 398-4563 |
| Auditor: Arthur Andersen | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 12/31/95 | ||||
| Revenue: | $10.04 | Assets: | $5.37 | ||
| Net Income: | -$2.09 | Liabilities: | $4.97 | ||
| EPS: | -$0.44 | Equity: | $0.40 | ||
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is developing proprietary anti-rejection pharmaceuticals and organ transplantation systems which represent a comprehensive approach to inducing long-term specific transplantation tolerance in humans. Specific transplantation tolerance would allow a transplant recipient to accept a donor organ as "self," while maintaining the remainder of the recipient's immune defenses. The company's product candidates are intended to reduce or eliminate the need for lifelong immunosuppressive therapy, minimize infections and complications associated with organ transplantation, reduce the cost of treating end-stage organ disease, and increase the supply of transplantable organs. Organ transplantation is an established therapy for end-stage organ disease. Approximately 35,000 kidney, liver, heart and lung transplants were performed in the United States and Western Europe in 1995. There is a critical shortage of organs worldwide, and large, growing lists have been established for potential organ transplant recipients. |
| Use of Proceeds |
| The proceeds from the offering will be used for research and development, preclinical programs, working capital and other general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.